Ratings Omnicell, Inc.

Equities

OMCL

US68213N1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
29.96 ^USD	-1.12%		+10.27%	-20.38%

May. 02	Omnicell Shares Rise After Q1 Non-GAAP Earnings, Revenue Beat Estimates	MT
May. 02	Transcript : Omnicell, Inc., Q1 2024 Earnings Call, May 02, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company has insufficient levels of profitability.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
OMNICELL, INC.	-20.38%	1.38B		B
VEEVA SYSTEMS INC.	+4.80%	32.61B		C
PRO MEDICUS LIMITED	+22.28%	7.98B		C-
SECTRA AB	+25.15%	3.99B		B-
EVOLENT HEALTH, INC.	-17.44%	3.13B		C-
LUNIT INC.	-30.40%	1.2B		-
SIMULATIONS PLUS, INC.	+7.28%	959M		C
B-SOFT CO.,LTD.	-34.66%	915M		-
VERADIGM INC.	-27.45%	819M	-	C+
SURGICAL SCIENCE SWEDEN AB	-18.08%	700M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes